Biohaven Pharma (BHVN) Misses Q3 EPS by 10c

Biohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.44), $0.10 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $0.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Sunbelt Rentals Holdings, Inc. (SUNB) Reports Q2 EPS of $1.18
• BMO cautious on softlines, bearish on athletic names